ACAD — ACADIA Pharmaceuticals Share Price
Last Trade - 00:00- $2.77bn
- $2.21bn
- $463.36m
Momentum
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | |||
| EPS Growth (f) | |||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | |||
| Price to Tang. Book | |||
| Price to Free Cashflow | |||
| Price to Sales | |||
| EV to EBITDA | |||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | |||
| Return on Equity | |||
| Operating Margin | |||
Financial Summary
| Year End 31st Dec | Unit | 2016 | 2017 | 2018 | 2019 | 2020 | 2021E | 2022E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 17.33 | 124.9 | 223.81 | 339.08 | 441.75 | 489.92 | 595.11 | 491.52% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Health trend(F-Score)
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
ACADIA Pharmaceuticals Inc. (ACADIA) is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines to address the medical needs in central nervous system disorders. The Company's lead product, NUPLAZID (pimavanserin), is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. ACADIA’s developments are focused on pimavanserin for additional neuropsychiatric conditions, trofinetide for Rett syndrome, ACP-044 for pain management and an early-stage muscarinic receptor program.
Directors
- Stephen Biggar NEC (50)
- Srdjan Stankovic PRE (64)
- Stephen Davis CEO (60)
- Elena Ridloff CFO (41)
- Austin Kim (57)
- Elizabeth Garofalo (64)
- Julian Baker IND (54)
- Laura Brege (63)
- James Daly IND (59)
- Edmund Harrigan (68)
- Daniel Soland (63)
- Last Annual
- December 31st, 2020
- Last Interim
- June 30th, 2021
- Incorporated
- January 16th, 1997
- Public Since
- May 27th, 2004
- No. of Shareholders
- 68,000
- No. of Employees
- 610
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Select Market
- Shares in Issue
- 160,643,284
- Address
- 3611 Valley Centre Dr Ste 300, SAN DIEGO, 92130-3331
- Web
- http://www.acadia-pharm.com/
- Phone
- +1 8585582871
- Contact
- Mark Johnson
- Auditors
- Ernst & Young LLP
Latest News for ACAD
Upcoming events for ACAD
Q3 2021 ACADIA Pharmaceuticals Inc Earnings Release
Similar to ACAD
4D MOLECULAR THERAPEUTICS ORD
NASDAQ Global Select Market
ABCELLERA BIOLOGICS ORD
NASDAQ Global Select Market
ABSCI ORD
NASDAQ Global Select Market
ACHILLES THERAPEUTICS ADS
NASDAQ Global Select Market
ACLARIS THERAPEUTICS ORD
NASDAQ Global Select Market
FAQ
As of Today at 19:54 UTC, shares in ACADIA Pharmaceuticals are trading at $17.24. This share price information is delayed by 15 minutes.
Shares in ACADIA Pharmaceuticals last closed at $17.24 and the price had moved by -56.31% over the past 365 days. In terms of relative price strength the ACADIA Pharmaceuticals share price has underperformed the S&P500 Index by -66.85% over the past year.
The overall consensus recommendation for ACADIA Pharmaceuticals is Hold. You can view the full broker recommendation list by unlocking its StockReport.
ACADIA Pharmaceuticals does not currently pay a dividend.
ACADIA Pharmaceuticals does not currently pay a dividend.
ACADIA Pharmaceuticals does not currently pay a dividend.
To buy shares in ACADIA Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $17.24, shares in ACADIA Pharmaceuticals had a market capitalisation of $2.77bn.
Here are the trading details for ACADIA Pharmaceuticals:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: ACAD
Based on an overall assessment of its quality, value and momentum ACADIA Pharmaceuticals is currently classified as a Falling Star. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in ACADIA Pharmaceuticals is $25.53. That is 48.09% above the last closing price of $17.24.
Analysts covering ACADIA Pharmaceuticals currently have a consensus Earnings Per Share (EPS) forecast of -$1.21 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like ACADIA Pharmaceuticals. Over the past six months, its share price has underperformed the S&P500 Index by -70.1%.
As of the last closing price of $17.24, shares in ACADIA Pharmaceuticals were trading -51.39% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
We are not able to find PE ratio data for ACADIA Pharmaceuticals.
ACADIA Pharmaceuticals' management team is headed by:
- Stephen Biggar - NEC
- Srdjan Stankovic - PRE
- Stephen Davis - CEO
- Elena Ridloff - CFO
- Austin Kim -
- Elizabeth Garofalo -
- Julian Baker - IND
- Laura Brege -
- James Daly - IND
- Edmund Harrigan -
- Daniel Soland -
We do not have data on ACADIA Pharmaceuticals' shareholders